CompletedPhase 2NCT03217643
CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.
Studying Enteropathy-associated T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Imagine Institute
- Principal Investigator
- Hermine OlivierHôpital Necker-Enfants Malades
- Intervention
- Brentuximab Vedotin(drug)
- Enrollment
- 14 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2018 – 2023
Study locations (1)
- Hopital Necker - Enfants malades, Paris, France
Collaborators
Takeda
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03217643 on ClinicalTrials.gov